Eli Lilly (LLY)
(Delayed Data from NYSE)
$807.43 USD
-1.02 (-0.13%)
Updated May 24, 2024 04:00 PM ET
After-Market: $808.30 +0.87 (0.11%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth D Momentum C VGM
Brokerage Reports
0 items in cart
Eli Lilly and Company [LLY]
Reports for Purchase
Showing records 421 - 428 ( 428 total )
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
First Quarter Results and Full Year Guidance Impacted by Health Care Legislation
Provider: J.J.B. Hilliard, W.L. Lyons
Analyst: O'NEIL S
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Biotech Balance Sheet
Provider: Merriman Curhan Ford & Co.
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
Biotech Balance Sheet
Provider: Merriman Curhan Ford & Co.
Company: Eli Lilly and Company
Industry: Large Cap Pharmaceuticals
High risk pipeline to drive long term growth..but concern remains over lack of near-term positive catalysts
Provider: FIRST GLOBAL
Analyst: THOMAS K
Company: Eli Lilly and Company
Industry: Medical - Drugs
Volume Gains More Apparent with Currency a Positive Factor. Development Pipeline Expanded..
Provider: J.J.B. Hilliard, W.L. Lyons
Analyst: O'NEIL S
Company: Eli Lilly and Company
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: ZENG G